Fig. 4: Reassessment of clinically tested drugs for ALS in motor neurons from SALS donors.

a, Schematic of the drug screen with 107 drugs previously tested in ALS clinical trials using patient-derived motor neurons from ALS donors across the patient population. b, Longitudinal quantification of the total neurite length of HB9-tGFP⁺ motor neurons following treatment with clinically tested drugs for ALS in a representative SALS donor (2.5 µM, expressed as a percentage of the pretreatment (day 36) value, mean of two wells/technical replicates ± s.e.m.). c, Images of motor neuron health at the screening endpoint (HB9-tGFP⁺ motor neuron clusters and neurites at 20×). d, Quantification of the average days of rescue of motor neurons from 16 SALS donors (one dot per donor, mean ± s.e.m., Kruskal–Wallis statistic with Dunn’s multiple comparisons test, main effect P < 0.0001, riluzole P = 0.0003, baricitinib P = 0.0049, memantine P = 0.0066, icapamespib P = 0.0135, fingolimod P = 0.0078, bosutinib P = 0.009 and colchicine P = 0.003, n = 16 donors). *P < 0.05. Scale bar (c), 100 µm.